A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

Publisher: John Wiley & Sons Inc

E-ISSN: 1097-0142|121|19|3481-3490

ISSN: 0008-543x

Source: CANCER, Vol.121, Iss.19, 2015-10, pp. : 3481-3490

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract